Albert David Limited (ALBERTDAVD.NS)
INR 835.7
(-3.08%)
INR 835.7
(-3.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.4 Billion INR | -35.55% |
| 2022 | 2.18 Billion INR | 12.09% |
| 2021 | 1.94 Billion INR | 23.13% |
| 2020 | 1.58 Billion INR | -24.78% |
| 2019 | 2.1 Billion INR | 3.64% |
| 2018 | 2.03 Billion INR | 4.69% |
| 2017 | 1.93 Billion INR | -7.88% |
| 2016 | 2.1 Billion INR | -1.17% |
| 2015 | 2.13 Billion INR | 2.51% |
| 2014 | 2.07 Billion INR | 15.3% |
| 2013 | 1.8 Billion INR | 9.04% |
| 2012 | 1.65 Billion INR | 7.85% |
| 2011 | 1.53 Billion INR | 5.21% |
| 2010 | 1.45 Billion INR | 9.49% |
| 2009 | 1.33 Billion INR | 10.75% |
| 2008 | 1.2 Billion INR | 15.38% |
| 2007 | 1.04 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 289.05 Million INR | 69.41% |
| 2023 Q3 | 554.8 Million INR | -9.83% |
| 2023 Q4 | 348.59 Million INR | -37.17% |
| 2023 Q1 | 602.61 Million INR | 18.17% |
| 2023 Q2 | 615.28 Million INR | 2.1% |
| 2023 FY | 1.4 Billion INR | -35.55% |
| 2022 Q1 | 589.82 Million INR | 35.24% |
| 2022 FY | 2.18 Billion INR | 12.09% |
| 2022 Q2 | 582.76 Million INR | -1.2% |
| 2022 Q4 | 509.95 Million INR | 1.54% |
| 2022 Q3 | 502.21 Million INR | -13.82% |
| 2021 Q2 | 534.86 Million INR | 2.85% |
| 2021 Q4 | 436.12 Million INR | -4.78% |
| 2021 FY | 1.94 Billion INR | 23.13% |
| 2021 Q1 | 520.04 Million INR | 45.54% |
| 2021 Q3 | 458.04 Million INR | -14.36% |
| 2020 Q3 | 424.22 Million INR | -6.19% |
| 2020 Q2 | 452.2 Million INR | 29.52% |
| 2020 Q1 | 349.14 Million INR | 4.19% |
| 2020 FY | 1.58 Billion INR | -24.78% |
| 2020 Q4 | 357.31 Million INR | -15.77% |
| 2019 Q4 | 335.11 Million INR | -36.12% |
| 2019 FY | 2.1 Billion INR | 3.64% |
| 2019 Q1 | 635.23 Million INR | 68.78% |
| 2019 Q2 | 609.6 Million INR | -4.04% |
| 2019 Q3 | 524.56 Million INR | -13.95% |
| 2018 Q2 | 527.63 Million INR | -16.95% |
| 2018 Q4 | 376.37 Million INR | -23.36% |
| 2018 FY | 2.03 Billion INR | 4.69% |
| 2018 Q1 | 635.32 Million INR | 34.98% |
| 2018 Q3 | 491.12 Million INR | -6.92% |
| 2017 Q2 | 619.79 Million INR | 67.78% |
| 2017 FY | 1.93 Billion INR | -7.88% |
| 2017 Q4 | 470.67 Million INR | -8.82% |
| 2017 Q3 | 516.22 Million INR | -16.71% |
| 2017 Q1 | 369.39 Million INR | -31.13% |
| 2016 Q3 | 444.91 Million INR | -27.77% |
| 2016 FY | 2.1 Billion INR | -1.17% |
| 2016 Q1 | 522.37 Million INR | 1.1% |
| 2016 Q2 | 615.96 Million INR | 17.92% |
| 2016 Q4 | 536.37 Million INR | 20.56% |
| 2015 Q3 | 485.61 Million INR | -24.21% |
| 2015 FY | 2.13 Billion INR | 2.51% |
| 2015 Q1 | 559.95 Million INR | 26.53% |
| 2015 Q2 | 640.77 Million INR | 14.43% |
| 2015 Q4 | 516.67 Million INR | 6.4% |
| 2014 Q3 | 489.75 Million INR | -22.4% |
| 2014 Q4 | 442.55 Million INR | -9.64% |
| 2014 Q2 | 631.08 Million INR | 22.58% |
| 2014 Q1 | 514.83 Million INR | 14.89% |
| 2014 FY | 2.07 Billion INR | 15.3% |
| 2013 Q3 | 392.55 Million INR | -24.5% |
| 2013 Q4 | 448.09 Million INR | 14.15% |
| 2013 Q1 | 441.9 Million INR | 20.83% |
| 2013 FY | 1.8 Billion INR | 9.04% |
| 2013 Q2 | 519.96 Million INR | 17.67% |
| 2012 Q1 | 416.98 Million INR | -3.24% |
| 2012 FY | 1.65 Billion INR | 7.85% |
| 2012 Q4 | 365.71 Million INR | 3.58% |
| 2012 Q3 | 353.08 Million INR | -31.67% |
| 2012 Q2 | 516.71 Million INR | 23.92% |
| 2011 Q4 | 430.94 Million INR | 42.33% |
| 2011 FY | 1.53 Billion INR | 5.21% |
| 2011 Q2 | 436.07 Million INR | 0.0% |
| 2011 Q3 | 302.77 Million INR | -30.57% |
| 2010 FY | 1.45 Billion INR | 9.49% |
| 2009 FY | 1.33 Billion INR | 10.75% |
| 2008 FY | 1.2 Billion INR | 15.38% |
| 2007 FY | 1.04 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -1145.775% |
| Aarti Drugs Limited | 8.31 Billion INR | 83.068% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 75.853% |
| Ajanta Pharma Limited | 21.06 Billion INR | 93.315% |
| Alembic Limited | 1 Billion INR | -40.794% |
| Alkem Laboratories Limited | 52.29 Billion INR | 97.308% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 94.742% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 77.372% |
| Bal Pharma Limited | 770.19 Million INR | -82.822% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -11124.289% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 61.897% |
| Brooks Laboratories Limited | 65.62 Million INR | -2045.82% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -211.418% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 84.706% |
| Divi's Laboratories Limited | 32.44 Billion INR | 95.659% |
| Eris Lifesciences Limited | 10.42 Billion INR | 86.495% |
| Granules India Limited | 16.79 Billion INR | 91.618% |
| Ind-Swift Limited | 2.17 Billion INR | 35.187% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -115.769% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 90.772% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 92.832% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -126.936% |
| Medicamen Biotech Limited | 495.49 Million INR | -184.178% |
| Medico Remedies Limited | 262.14 Million INR | -437.143% |
| Wockhardt Limited | 7.72 Billion INR | 81.761% |
| Orchid Pharma Limited | 2.32 Billion INR | 39.315% |
| RPG Life Sciences Limited | 2.48 Billion INR | 43.291% |
| Shilpa Medicare Limited | 3.56 Billion INR | 60.468% |
| Sigachi Industries Limited | 2 Billion INR | 29.676% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 185.035% |
| Unichem Laboratories Limited | 4.86 Billion INR | 71.056% |
| Vaishali Pharma Limited | 90.32 Million INR | -1458.946% |
| Wanbury Limited | 1.73 Billion INR | 18.638% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.875% |
| FDC Limited | 6.58 Billion INR | 78.621% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 32.757% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 4.329% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.139% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 88.675% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 65.932% |
| Laurus Labs Limited | 15.44 Billion INR | 90.885% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -103.718% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 70.807% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -166.111% |
| Hester Biosciences Limited | 1.27 Billion INR | -10.555% |
| Ipca Laboratories Limited | 48.58 Billion INR | 97.102% |
| Venus Remedies Limited | 2.18 Billion INR | 35.485% |
| ZIM Laboratories Limited | 1.26 Billion INR | -11.064% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 98.715% |
| Morepen Laboratories Limited | 6.16 Billion INR | 77.146% |
| Neuland Laboratories Limited | 8.24 Billion INR | 82.928% |
| Sequent Scientific Limited | 2.97 Billion INR | 52.729% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 65.85% |
| Valiant Laboratories Limited | 138.02 Million INR | -920.139% |
| Windlas Biotech Limited | 1.33 Billion INR | -5.175% |
| Hikal Limited | 5.95 Billion INR | 76.366% |
| Innova Captab Limited | 3.46 Billion INR | 59.356% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 75.645% |
| Themis Medicare Limited | 2.42 Billion INR | 41.815% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 70.162% |
| Mankind Pharma Limited | 42.19 Billion INR | 96.663% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 97.969% |
| Sakar Healthcare Limited | 699.58 Million INR | -101.275% |
| Lupin Limited | 125.09 Billion INR | 98.874% |
| Gufic Biosciences Limited | 4.07 Billion INR | 65.435% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.455% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 25.374% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -151.667% |
| Piramal Enterprises Limited | 8.04 Billion INR | 82.494% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 96.989% |
| NATCO Pharma Limited | 25.73 Billion INR | 94.529% |
| Suven Life Sciences Limited | -200.79 Million INR | 801.249% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 1394.828% |
| Strides Pharma Science Limited | 14.38 Billion INR | 90.214% |
| Indoco Remedies Limited | 8.04 Billion INR | 82.493% |
| Alpa Laboratories Limited | 188.89 Million INR | -645.434% |
| Lasa Supergenerics Limited | 121.02 Million INR | -1063.42% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -260.064% |